CACNG1
ENSG00000108878
Target class
Auxiliary transport protein
Chromosome
17
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNG1
- Gene name
- Calcium voltage-gated channel auxiliary subunit gamma 1
- Gene symbol
- CACNG1
- Previous gene symbols
- CACNLG
- Protein name
- Voltage-dependent calcium channel gamma-1 subunit (Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma)
- Gene biotype
- Protein coding
- Gene family
- Calcium channel auxiliary gamma subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 6
- Highest tissue expression
- 226.6
- Tissue specificity (Gini)
- 0.963
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:786
- Protein interaction confidence
- 0.847159
- Protein interaction partners
- 44
- End position
- 67056797
- Start position
- 67044554
- Chromosome
- 17
- Strand
- Forward
- Cell membrane, sarcolemma
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.99871
- Expression inequality (Gini)
- 0.962909
Expression in transcripts per million
- Muscle - Skeletal
- 226.6
- Brain - Nucleus accumbens (basal ganglia)
- 2.36
- Brain - Caudate (basal ganglia)
- 1.83
- Adrenal Gland
- 1.78
- Brain - Putamen (basal ganglia)
- 1.62
Expression in transcripts per million
- Muscle - Skeletal226.6
- Brain - Nucleus accumbens (basal ganglia)2.36
- Brain - Caudate (basal ganglia)1.83
- Adrenal Gland1.78
- Brain - Putamen (basal ganglia)1.62
- Brain - Amygdala1.07
- Brain - Anterior cingulate cortex (BA24)0.79
- Prostate0.68
- Brain - Hypothalamus0.57
- Brain - Cortex0.52
- Brain - Frontal Cortex (BA9)0.44
- Brain - Hippocampus0.42
- Minor Salivary Gland0.39
- Brain - Cerebellum0.39
- Brain - Cerebellar Hemisphere0.25
- Brain - Substantia nigra0.25
- Breast - Mammary Tissue0.23
- Lung0.23
- Brain - Spinal cord (cervical c-1)0.17
- Fallopian Tube0.13
- Stomach0.12
- Testis0.12
- Nerve - Tibial0.08
- Artery - Tibial0.07
- Skin - Sun Exposed (Lower leg)0.07
And 29 more, listed on the interactive page.
Molecular functions
- GO:0005515
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker